

## Metivier, Jacob

---

**From:** Brian Ushler <Brian.Ushler@Eversana.com>  
**Sent:** Friday, June 16, 2023 8:38 AM  
**To:** AGO - High Cost Prescription Drugs  
**Cc:** Stephanie O 'Dwyer  
**Subject:** Notice of New Prescription Drug MPD – Shorla Oncology

**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

Some people who received this message don't often get email from brian.ushler@eversana.com. [Learn why this is important](#)

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

To Whom It May Concern:

This email is to inform the Attorney General's Office for the State of Vermont that Shorla Oncology has launched a new reportable product and therefore to meet the requirements of 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs). Nelarabine is a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. Please see the below information to comply with Vermont's submission requirements.

- The product was not granted a breakthrough therapy designation
- The product was given priority review by the FDA.
- Nelarabine is a generic physician administered oncology product. Shorla Oncology will be marketing the product to pharmacists and oncologists and will be pricing the product at parity to the market/competitors.
- The estimated volume of patients is approximately 555 per month.

Please contact us with any questions.

**Brian Ushler**

Revenue Management & Compliance Solutions

**Direct/Cell:** +1 (267) 218-0683

[brian.ushler@eversana.com](mailto:brian.ushler@eversana.com)

[www.eversana.com](http://www.eversana.com)



**EVERSANA™**

**IMPORTANT NOTICE:** The information contained in this communication is for the sole use of the intended recipient(s) and may contain confidential information. If you are not an intended recipient, you are hereby notified that any use, disclosure, copying or distribution of this communication or its contents is strictly prohibited. If you have received this communication in error, please contact the sender immediately and delete the original message and any copies from your computer system.